Blockade of CXCR4, the CXCL12 receptor, in the KPC mouse model not only leads to a rapid accumulation of CD8+ T cells in the vicinity of cancer cells but also enhances the effectiveness of anti-PD-L1 therapy [119]. This evidence concerns the gene CD8A and cancer.